DE60027913D1 - 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz - Google Patents

5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz

Info

Publication number
DE60027913D1
DE60027913D1 DE60027913T DE60027913T DE60027913D1 DE 60027913 D1 DE60027913 D1 DE 60027913D1 DE 60027913 T DE60027913 T DE 60027913T DE 60027913 T DE60027913 T DE 60027913T DE 60027913 D1 DE60027913 D1 DE 60027913D1
Authority
DE
Germany
Prior art keywords
treatment
derivatives
sapogenine
pseudosapogenine
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60027913T
Other languages
English (en)
Other versions
DE60027913T2 (de
Inventor
Paul Barraclough
Jim Hanson
Phil Gunning
Daryl Rees
Zongqin Xia
Yaer Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytopharm Ltd
Original Assignee
Phytopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Ltd filed Critical Phytopharm Ltd
Application granted granted Critical
Publication of DE60027913D1 publication Critical patent/DE60027913D1/de
Publication of DE60027913T2 publication Critical patent/DE60027913T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE60027913T 1999-09-29 2000-09-29 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz Expired - Lifetime DE60027913T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9923076 1999-09-29
GBGB9923076.5A GB9923076D0 (en) 1999-09-29 1999-09-29 Sapogenin derivatives and their use
PCT/GB2000/003737 WO2001023406A1 (en) 1999-09-29 2000-09-29 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

Publications (2)

Publication Number Publication Date
DE60027913D1 true DE60027913D1 (de) 2006-06-14
DE60027913T2 DE60027913T2 (de) 2007-01-11

Family

ID=10861837

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027913T Expired - Lifetime DE60027913T2 (de) 1999-09-29 2000-09-29 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz

Country Status (27)

Country Link
US (2) US7138427B2 (de)
EP (2) EP1724279A2 (de)
JP (1) JP2003510332A (de)
KR (1) KR100771491B1 (de)
CN (2) CN100445295C (de)
AT (1) ATE325808T1 (de)
AU (1) AU778294C (de)
BR (1) BR0014381A (de)
CA (2) CA2385402C (de)
CY (1) CY1105225T1 (de)
CZ (1) CZ300150B6 (de)
DE (1) DE60027913T2 (de)
DK (1) DK1224205T3 (de)
ES (1) ES2260055T3 (de)
GB (1) GB9923076D0 (de)
HK (1) HK1045525B (de)
HR (2) HRP20020255A2 (de)
IL (2) IL148920A0 (de)
MX (1) MXPA02003305A (de)
NO (1) NO324959B1 (de)
NZ (1) NZ518596A (de)
PT (1) PT1224205E (de)
RU (1) RU2325396C2 (de)
TR (1) TR200200821T2 (de)
UA (1) UA82978C2 (de)
WO (1) WO2001023406A1 (de)
ZA (1) ZA200202382B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
NZ535093A (en) * 2002-03-27 2006-09-29 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
EP2111864A3 (de) * 2002-03-27 2009-12-30 Phytopharm Plc Therapeutische Verfahren und Verwendungen von Sapogeninen und deren Derivaten
NZ547897A (en) * 2002-03-27 2008-02-29 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
TWI334781B (en) * 2002-10-28 2010-12-21 Phytopharm Plc Stereospecific synthesis of sapogenins
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
KR20110115589A (ko) 2009-01-24 2011-10-21 파이토팜 피엘씨 신경영양인자가 매개된 장애의 치료
CN101768202B (zh) * 2009-02-18 2013-10-30 沈阳药科大学 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途
MX2013000760A (es) 2010-07-20 2013-10-28 Phytopharm Plc Tratamiento de trastornos inducidos por l-dopa, agonista de la dopamina y/o potenciador de dopamina.
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
US11319338B2 (en) 2012-04-03 2022-05-03 Goldporp Pharma Limited Timosaponin compounds
CN102924559B (zh) * 2012-11-16 2015-10-28 沈阳药科大学 菝葜皂苷元衍生物及其制备和应用
GB201305708D0 (en) * 2013-03-28 2013-05-15 Clasado Inc Novel use
CN103232520A (zh) * 2013-05-13 2013-08-07 中国药科大学 一种螺甾类化合物、其制备方法及医药用途
CN104513289B (zh) * 2015-01-27 2017-12-22 华东理工大学 知母皂苷元结构修饰的衍生物、其药物组合物及其应用
CA3001510C (en) * 2015-10-29 2022-05-24 Emmyon, Inc. Furostan-3-ol derivatives as skeletal muscle hypertrophic agents
CN106977581B (zh) * 2017-04-17 2021-01-01 华东理工大学 知母皂苷元结构修饰的衍生物的应用以及药物组合物

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852847A (en) 1958-03-04 1960-11-02 British Drug Houses Ltd Improvements in or relating to 6-methyl steroid compounds
US3575810A (en) * 1967-07-19 1971-04-20 Takashi Matsushima Method for removal of side chain of sapogenins
BE794362A (fr) 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3929769A (en) 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (de) 1974-04-08 1975-10-09 Degussa Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff
LU81256A1 (fr) 1979-05-15 1980-12-16 Oreal Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides
IT1144136B (it) 1980-03-05 1986-10-29 Zenyaku Kogyo Kk Glucosidi di condurango agenti antitumorali che li comprendono e procedimento per la loro preparazione
GB2097672A (en) 1981-05-01 1982-11-10 Pattni Ramesh Damji Devji Process for extraction of crude sapogenins from Agave Leaves
JPS5855500A (ja) 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk １６−デヒドロプレグネノロンの製造法
US4602005A (en) 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4562250A (en) 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPS62234025A (ja) 1986-04-03 1987-10-14 Asahi Chem Ind Co Ltd 老人性痴呆者用食品
US5017562A (en) 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (de) 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
JPH02188528A (ja) 1989-01-13 1990-07-24 Tsurataka Tashiro 痴呆症治療薬
BR9105952A (pt) 1990-01-18 1992-11-17 Cura Nominees Pty Ltd Metodo para identificar composto e para controlar autofagia celular,aglutinacao ou imobilizacao celulares de celulas moveis,metodo para tratamento de cancer,contracepcao,termino de gravidez,remocao de organismos patogenicos e de desenvolvimento celular anormal,metodo de induzir autofagia celular,aglutinacao ou imobilizacao celulares em um corpo animal,metodo de marcar e identificar celula-alvo,composto e composicao contendo pelo menos um composto para controlar autofagia celular,aglutinacao ou imobilizacao celuares de celulas moveis
SE9100342D0 (sv) 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
US5252729A (en) 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
CZ331094A3 (en) 1992-06-26 1995-09-13 Pfizer Steroidal glycosides and their use for treating hypercholesterolemia and atherosclerosis
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
WO1994018994A1 (en) 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Therapeutic herbal composition
CN1092992A (zh) 1993-03-29 1994-10-05 中国科学院沈阳应用生态研究所 提高脑功能的药物及其制备方法
CN1052636C (zh) 1993-03-29 2000-05-24 中国科学院沈阳应用生态研究所 文冠果子的醇提取物在制备治疗智力低下的药物中的应用
JPH06305952A (ja) 1993-04-27 1994-11-01 Sumitomo Pharmaceut Co Ltd スレオ−３−（３，４−ジヒドロキシフェニル）セリン経鼻投与製剤
SK135195A3 (en) 1993-04-28 1996-03-06 Pfizer Crystaline spirostalnylglycosidal, its monohydrate pharmaceutical agent on its base and method of production of crystaline steroid glycoside
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
CN1102186A (zh) 1993-10-29 1995-05-03 沈阳医学院 中药薤白新成分的鉴定及用途
US5589182A (en) 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
JPH09500906A (ja) 1993-12-28 1997-01-28 ファイザー・インク． 血中コレステロール低下薬
CA2180149A1 (en) 1993-12-28 1995-07-06 Michael Paul Deninno Steroidal glycosides
IL109614A (en) 1994-05-10 1998-06-15 Yissum Res Dev Co Comestible products containing saponins
US5563131A (en) 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
CA2198097A1 (en) 1994-08-30 1996-03-07 Douglas J. Allen Spirostanyl glycosidal crystals
AU2453295A (en) 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US6150336A (en) 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
JPH09100295A (ja) 1995-06-13 1997-04-15 Toray Ind Inc 新規トリテルペノイドサポニン類およびそれを有効成分とする神経突起伸展作用を有する治療剤
CU22860A1 (es) 1995-10-12 2003-05-26 Univ La Habana Espirostanonas con funciones oxigenadas en el anillo a. como reguladores del crecimiento vegetal y su procedimiento de obtención
AU7145996A (en) 1995-10-13 1997-04-30 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
FR2743561B1 (fr) 1996-01-15 1998-02-20 Fournier Sca Lab Derives de steroides, procede de preparation et utilisation en therapeutique
KR0169536B1 (ko) 1996-02-27 1999-01-15 손경식 신규한 인삼 사포닌, 그의 제조방법 및 이를 유효성분으로 하는 항종양제
US5726179A (en) 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
WO1997042958A1 (en) 1996-05-09 1997-11-20 Amrad Operations Pty. Ltd. Treatment of asthma and airway diseases
EP0930876B2 (de) 1996-07-22 2010-07-07 Renovo Limited Verwendung von substanzen, die die östrogen wirkung fördern, zur beschleunigung der heilung von hautwunden
US5804239A (en) 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
EP1019044B1 (de) 1997-05-15 2007-04-11 University of Washington Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen
WO1998058650A1 (en) 1997-06-20 1998-12-30 University Of Utah Research Foundation Use of plant-alkaloids to enhance innate immunity defense mechanisms
CA2301860C (en) 1997-08-28 2009-05-26 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
JP3906948B2 (ja) * 1997-09-13 2007-04-18 本田技研工業株式会社 電動式変速装置の変速制御装置
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
CA2217088A1 (en) 1997-09-30 1999-03-30 Universite De Sherbrooke New mandevilla velutina derivatives as steady-state r-type ca2+ channel blockers, method of making and use thereof
JP3873097B2 (ja) 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9905275D0 (en) 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
AU748138B2 (en) * 1998-03-26 2002-05-30 Phytopharm Plc. Steroidal sapogenins and their derivatives for treating alzheimers disease
KR100292406B1 (ko) * 1998-06-11 2001-07-12 윤종용 감광성중합체,용해억제제및이들을포함하는화학증폭형포토레지스트조성물
GB2347676A (en) 1999-03-08 2000-09-13 Phytopharm Plc Screening method
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPP968699A0 (en) 1999-04-09 1999-05-06 Cura Nominees Pty Ltd Therapeutic compositions and method for their preparation
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
BR0001794A (pt) 2000-05-15 2001-12-26 Laboratorios Biosintetica Ltda Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
US20050130948A1 (en) 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives

Also Published As

Publication number Publication date
IL148920A0 (en) 2002-09-12
DK1224205T3 (da) 2006-06-12
CA2385402C (en) 2009-01-13
DE60027913T2 (de) 2007-01-11
KR100771491B1 (ko) 2007-10-30
US20030004147A1 (en) 2003-01-02
TR200200821T2 (tr) 2002-06-21
NO324959B1 (no) 2008-01-14
EP1724279A2 (de) 2006-11-22
GB9923076D0 (en) 1999-12-01
JP2003510332A (ja) 2003-03-18
CA2640998A1 (en) 2001-04-05
CY1105225T1 (el) 2010-03-03
NO20021541D0 (no) 2002-03-27
US20060100184A9 (en) 2006-05-11
PT1224205E (pt) 2006-08-31
RU2325396C2 (ru) 2008-05-27
EP1224205B1 (de) 2006-05-10
EP1224205A1 (de) 2002-07-24
ES2260055T3 (es) 2006-11-01
ATE325808T1 (de) 2006-06-15
AU778294B2 (en) 2004-11-25
WO2001023406A1 (en) 2001-04-05
AU778294C (en) 2005-08-04
HK1045525B (zh) 2006-08-04
US7138427B2 (en) 2006-11-21
NZ518596A (en) 2004-07-30
BR0014381A (pt) 2002-06-25
IL180972A0 (en) 2007-07-04
HRP20080467A2 (en) 2008-11-30
UA82978C2 (ru) 2008-06-10
ZA200202382B (en) 2003-09-23
KR20020092914A (ko) 2002-12-12
CN1377368A (zh) 2002-10-30
CN100445295C (zh) 2008-12-24
AU7537500A (en) 2001-04-30
CN101411712A (zh) 2009-04-22
CZ300150B6 (cs) 2009-02-25
US7507720B2 (en) 2009-03-24
HK1045525A1 (en) 2002-11-29
PL357370A1 (en) 2004-07-26
MXPA02003305A (es) 2002-10-04
NO20021541L (no) 2002-05-28
HRP20020255A2 (en) 2003-08-31
CA2385402A1 (en) 2001-04-05
US20060276415A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE60137307D1 (de) Substituierte sapogenine und ihre verwendung
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE314057T1 (de) Smilagenin und anzurogenin-d zur behandlung der alzheimerischen krankheit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60022867D1 (de) 1-Arenesulfonyl-2-Aryl-Pyrrolidin und Piperidin Derivative zur Behandlung von CNS-Erkrankungen
ATE277072T1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
GB9923078D0 (en) Sapogenin derivatives and their use
DE60001725D1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
ATE375160T1 (de) Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
DE60125915D1 (de) Verfahren zur herstellung von quinolin-derivaten und ihre zwischenstufen
DE50113300D1 (de) Verwendung von erythropoietin sowie dessen derivate zur behandlung von schizophrenie und verwandten psychosen
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis
ATE263139T1 (de) 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie
MY134920A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
DE60037349D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Tumoren
DE69833655D1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition